Result from a Phase 1b clinical study evaluating the safety and clinical activity of the triple combination of Roche's a $RHHBY�COTELLIC (cobimetinib), ZELBORAF (vemurafenib) and TECENTRIQ (atezolizumab) in treatment-naive patients with BRAF V600-positive advanced melanoma showed a positive treatment benefit although with side effects. The data will be made public on Monday, October 10 at the European Society of Medical Oncology 2016 Congress in Copenhagen.